May 15th 2024
“The association of lower testosterone concentrations with higher all-cause mortality was present irrespective of luteinizing hormone concentrations, indicating that low testosterone was the main factor," says Bu B. Yeap, MBBS, FRACP, PhD.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
(Slideshow) The University of Utah’s men’s health clinic
October 8th 2014Men’s health clinics are becoming a place where men can come in and get all or most of their health care needs met in one visit. These clinics, the subject of a recent article in Urology Times, differ in design and layout but are the same in their focus on providing comprehensive health care for men. This slideshow offers a look at the Center for Reconstructive Urology and Men’s Health, University of Utah, Salt Lake City
(Slideshow) Men’s Health Center at The Miriam Hospital
October 8th 2014Building fellowships in male andrology and broader men’s health is becoming a key role in training younger physicians in the field for men’s health clinics. These clinics, the subject of a recent article in Urology Times, differ in design and layout but are the same in their focus on providing comprehensive health care for men.
Three key design elements for men's health clinics
October 8th 2014Urologists and internists who direct successful comprehensive men’s health centers in the U.S. say these centers need to do more than cater to men’s health needs. They should also cater to men’s wants. Specifically, here are three design elements you should incorporate into your men’s health center, if you haven’t done so already.
Urologists helping drive male-specific centers
October 7th 2014Multidisciplinary men’s health centers, rooted at hospitals, academic centers, and some private clinics, have expanded in the last few years and are meeting an important need in medicine, say key figures in these centers. Urologists are helping to drive these clinics’ success.
(Slideshow) Preston Robert Tisch Center for Men's Health
October 7th 2014Men’s health clinics are a growing trend centered around the global care of men and the philosophy that men need to be taken care of in a holistic way. These clinics, the subject of a recent article in Urology Times, differ in design and layout but are the same in their focus on providing comphrensive health care for men.
Second agent shows significant benefit in mCRPC pre-chemo
October 6th 2014Abiraterone acetate (ZYTIGA) as therapy for chemotherapy-naïve metastatic castration-resistant prostate cancer improved overall survival by a statistically significant 19% compared with placebo in the final analysis of the phase III COU-AA-302 clinical trial.
AUA checklist a resource for common men’s health issues
October 6th 2014The AUA’s Committee on Male Health has developed a checklist to serve as a resource of urologic and non-urologic men’s health considerations. Intended for urologists and other health care providers, it is also aimed at better coordinating care among men’s providers.
USPSTF PSA grade has ‘minimal’ impact on screening
September 29th 2014The effect of the U.S. Preventive Services Task Force’s controversial grade “D” recommendation regarding PSA-based screening for prostate cancer “has been minimal at best,” according to a research letter that also shows a “shocking” level of statewide variance in screening, a leading prostate cancer expert said.
Medicare to cover one PCa test, PPO covers another
September 29th 2014The ConfirmMDx for Prostate Cancer test qualifies for Medicare coverage effective Nov. 3, 2014, MDxHealth SA announced, while the maker of a second test, the Decipher Prostate Cancer Classifier, has added a new preferred provider organization to expand coverage of that test.
Data suggest racial disparity in high-risk PCa treatment
September 29th 2014Results of a study analyzing data from the Surveillance, Epidemiology, and End Results program add to evidence of race-related disparity in receipt of treatment for prostate cancer, but show that having health insurance reduces the difference in care.
DHEA levels may predict response to advanced PCa agent
September 29th 2014Results of a phase II study from the Prostate Cancer Clinical Trials Consortium show that abiraterone acetate (ZYTIGA) has modest clinical activity in men with progressive metastatic castrate-resistant prostate cancer previously treated with ketoconazole.
ADT overuse remains a problem among some urologists
September 24th 2014Inappropriate use of a gonadotropin-releasing hormone agonist for androgen deprivation therapy of localized prostate cancer fell dramatically following implementation of reimbursement cuts mandated by the Medicare Modernization Act of 2003, but overuse remains problematic, according to research presented at the American Society of Clinical Oncology annual meeting in Chicago.
Low-risk PCa: Patients can make an informed decision
September 23rd 2014In this interview, Ian Thompson, MD, answers questions about the downside of diagnosing low-risk prostate cancer, the burdens of active surveillance and how to minimize them, and how his own approach to screening and biopsy have changed.
PCa test predicts aggressiveness, influences treatment
September 22nd 2014The Decipher Prostate Cancer Classifier test predicts disease aggressiveness, influences treatment decisions, and predicts which patients may benefit from post-prostatectomy radiation therapy, according to findings from three studies presented at the American Society for Radiation Oncology annual meeting in San Francisco.
FDA panel’s vote on TRT draws reaction from urologists
September 22nd 2014An FDA advisory committee has voted to restrict indications for testosterone replacement therapy and require additional clinical trials to test the safety of the drugs, decisions that have drawn mixed reactions from urologists.
Oncofertility: Current practice and vision for the future
September 19th 2014In this article, Ahmed A. Hussein, MD, and James F. Smith, MD, MS, examine the effect of malignancy and anti-cancer treatment on fertility, review current fertility preservation methods, and offer a preview of fertility preservation techniques that hold future promise.
Approval of enzalutamide pre-chemo a ‘game changer’
September 16th 2014The FDA’s approval of enzalutamide (XTANDI) to treat metastatic castration-resistant prostate cancer (CRPC) in the pre-chemotherapy setting is a potential game changer for both patients and treating physicians, especially urologists, according to leaders in the prostate cancer field.
AR splice variant predicts resistance to PCa treatments
September 8th 2014Metastatic castration-resistant prostate cancer patients whose tumors contain the androgen receptor (AR)-V7 splice variant are less likely to respond to enzalutamide (XTANDI) and abiraterone acetate (ZYTIGA), recent study results indicate.
Low Estrogen could mean low Testosterone (VIDEO)
September 5th 2014Low testosterone is often blamed for a lower sex drive and potentially dangerous fat accumulation in men, however researchers from Massachusetts General Hospital report that a lack of estrogen is also to blame. Video provided by Renal & Urology News.
High-volume surgeons show multiple options for IPP placement
September 2nd 2014In this first installment of UrologyTimes.com's new video section, called ‘Y’tube, we present videos from high-volume prosthetic surgeons performing inflatable penile prosthesis (IPP) placement and discussing diagnosis and management of ED. William O. Brant, MD, offers the following general commentary about these procedures, as well as specific comments in the text accompanying each individual video.